FGF21 has demonstrated signifcant increase in glucose uptake in mouse 3T3-L1 and primary human adipocytes and also mitigated plasma glucose and triglyceride levels in genetic mouse models of obesity and type 2 diabetes, hence, eliciting enormous interest as a potential therapeu tic agent . Since this discovery, many studies have been in this direction to confrm the thera peutic role of FGF21 in a number of animal models with signifcant results in blood glucose and insulin reduction, improved insulin sensitivity, energy expenditure and lipid metabolism .